<DOC>
	<DOCNO>NCT00053209</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , gemcitabine , work different way stop tumor cell divide stop grow die . Combining pemetrexed disodium gemcitabine may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine pemetrexed disodium gemcitabine treat patient advanced cancer urothelium .</brief_summary>
	<brief_title>Pemetrexed Disodium Gemcitabine Treating Patients With Advanced Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient previously untreated advanced cancer urothelium treat pemetrexed disodium gemcitabine . - Determine toxicity regimen patient . Secondary - Determine overall survival time progression patient treat regimen . OUTLINE : This multicenter study . Patients receive pemetrexed disodium IV 10 minute day 1 gemcitabine IV 30 minute day 1 8 . Patients also receive cyanocobalamin intramuscularly every 9 week folic acid orally daily begin day -6 continue 3 week completion study therapy . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 24-46 patient accrue study within 15 -18 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cancer urothelium ( renal pelvis , ureter , bladder , urethra ) Any follow type : Transitional cell carcinoma ( TCC ) Mixed histology contain component TCC NonTCC urothelium ( renal pelvis , ureter , bladder , urethra ) Progressing regional metastatic disease Measurable disease No clinical evidence CNS metastases No evidence clinically significant ( physical exam plain film ) thirdspace fluid collection ( pleural effusion ascites ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic AST great 3 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN Renal Creatinine clearance least 45 mL/min Cardiovascular No history severe cardiovascular disease ( i.e. , American Heart Association class III IV heart disease ) No uncontrolled congestive heart failure No ventricular dysrhythmias Other Not pregnant nursing Fertile patient must use effective contraception No active unresolved infection No prior malignancy unless curatively treated disease free appropriate ( diseasespecific ) period time Able willing receive folic acid cyanocobalamin supplementation PRIOR CONCURRENT THERAPY : Biologic therapy No prior systemic biologic response modifier therapy Chemotherapy No prior systemic chemotherapy metastatic disease More 1 year since prior neoadjuvant adjuvant chemotherapy Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy recover No prior pelvic radiotherapy No concurrent radiotherapy Surgery At least 4 week since prior major surgery recover Other More 7 day since prior parenteral antibiotic No salicylate 2 day , , 2 day administration pemetrexed disodium No nonsteroidal antiinflammatory drug least 5 day , , 2 day administration pemetrexed disodium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>